

REMARKS

Reconsideration is requested.

Claims 35, 37, 38, 43, 44 and 46-64 are pending. Claims 38, 48-56 and 62-64 have been withdrawn from consideration.

Claims 35, 37, 57 and 61 have been amended without prejudice, as suggested by the Examiner (see end of page 5 and pages 7 and 8 of the Office Action dated August 24, 2007) to obviate the Section 112, first paragraph, rejections of claims 35, 37, 41-44, 46, 47 and 57-61. The revised claims are further submitted to obviate the Section 112, second paragraph, rejection of claims 35, 37, 43, 44, 46, 47 and 57-61.

Consideration of the above and the following, and withdrawal of the Section 112, first and second paragraph, rejections are requested.

Specifically, claim 35 specifies that the mouse is a transgenic mouse whose genome comprises a mutant LAT gene, or one allele for a mutant mouse LAT gene, encoding a mutant mouse LAT protein, wherein the sequence of said mutant mouse LAT protein comprises a single mutation of a tyrosine located at position 136 of the wild-type mouse LAT protein sequence, wherein the mutation is not a composite mutation of the tyrosine residues at positions 175, 195, and 235 of said wild-type mouse LAT protein sequence, wherein the single mutation of the tyrosine located at position 136 consists of a replacement with a residue preventing the association with the SH2 domain of proteins, wherein the mouse is homozygous for said mutant mouse LAT gene, or is a carrier of a null allele of the LAT gene, and wherein the mouse has a phenotype of exaggerated TH2 cell differentiation. Claims 37 and 61 refer to SEQ ID

MALISSEN et al
Appl. No. 10/502,332
Monday, November 26, 2007
Amendment

NO:3, as opposed to SEQ ID NO:2. The claims are believed to be supported by an adequate written description, as is believed to be acknowledged by the Examiner.

The claims have been revised without prejudice or disclaimer and solely in order to facilitate reconsideration of this application. In particular, applicant reserves his right to file a divisional and/or continuation application at a later stage, and the present amendment shall not be considered as an admission of the objection or as a waiver of any subject matter.

The claims are submitted to be in condition for allowance and a Notice to that effect is requested. The Examiner is requested to contact the undersigned, preferably by telephone, in the event anything further is required to place the application in condition for allowance.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____ /B. J. Sadoff/
B. J. Sadoff
Reg. No. 36,663

BJS:
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100